SCT800
Phase 3Biologic
SCT800 is one of 19 biologic programs targeting Hemophilia A. It is currently in Phase 3.
1
Indications
4
Total Trials
2
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Hemophilia a
#DrugCompanyPhaseTrials
1Hemlibra
RocheApproved
Rayos
RRoxane Laboratories
Approved
Cyklokapron
JJ Molner
Approved
Efanesoctocog Alfa
SanofiPhase 3
Advate
TakedaPhase 3
Marstacimab
PfizerPhase 3
PF-06741086
PfizerPhase 3
Rfviia
RochePhase 3
NXT007
RochePhase 3
SR604
EEquilibra Bioscience LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hemophilia A4 trials
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT05888870·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCT800. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- SSinocelltech Ltd.